【国联民生医药】艾力斯2025年业绩预告点评:肺癌领域深度布局,自主商业化能力持续增强

医耀科技创新骑手
Feb 02

事件:艾力斯发布2025年年度业绩预增公告,预计2025年度实现营业收入52.0亿元,比上年同期增加16.4亿元,同比增加46.15%;归母净利润为21.5亿元,比上年同期增加7.2亿元,同比增加50.37%;扣除非经常性损益后的归母净利润为20亿元,比上年同期增加6.4亿元,同比增加46.95%。业绩增长的主要原因:艾力斯商业化产品聚焦肺癌精准治疗领域,通过差异化的临床治疗优势和专业化的学术推广...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10